A Phase 3 interventional study of Buprenorphine and Buprenorphine in Osteoarthritis, sponsored by Purdue Pharma LP. Terminated at 23 sites in United States. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2012-09-10.
Sponsored by Purdue Pharma LP (part of Knoa Pharma) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies testing buprenorphine in Osteoarthritis — none open to participants now, none under way, none of them phase 3. Buprenorphine · Osteoarthritis.
Among the 19 studies testing buprenorphine in Osteoarthritis, this one is the 2nd largest by enrollment, is one of 3 that started in 2004, is one of 11 in phase 3, and was the 1st registered.
2,977 studies on the registry are indexed under Osteoarthritis; 438 are open to participants now.
Browse Osteoarthritis studies →None of the 19 studies testing buprenorphine in Osteoarthritis is open now. The open studies under Osteoarthritis, anywhere →
Buprenorphine: first FDA approval 1981 (BUPRENEX), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →
Of the 285 Osteoarthritis studies recruiting now, 157 (55%) set no upper age limit and 71 (25%) stop at 75 or younger; 22 take children under 18; 30 take healthy volunteers.
This study: 40 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 1996; this study’s year is marked. 3 started in 2004.
This study's enrollment of 418 is above the median of 80 across 2,241 interventional studies indexed under Osteoarthritis.
Median enrollment 196 across the 19 interventional studies. Of the 19 that completed or were terminated, 11 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 19 have an industry lead sponsor. The 10 most frequent:
This study is registered under Purdue Pharma LP, one of the names counted as Knoa Pharma. Under that name alone:
Purdue Pharma LP is the lead sponsor of 58 studies on the registry; none are open to participants now.
12 studies in Osteoarthritis by Knoa Pharma: none open now, none under way, none of them phase 3. Of 12 finished, 8 (67%) have results posted.
Among the 12 studies in Osteoarthritis by Knoa Pharma, this one is the 2nd largest by enrollment, is one of 3 that started in 2004, is one of 9 in phase 3, and was the 1st registered.
Knoa Pharma’s Osteoarthritis studies by the year they started, since 1996.
None of the studies under way reaches primary completion within a year.
Among the 19 studies testing buprenorphine in Osteoarthritis, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Knoa Pharma’s 12 in Osteoarthritis:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The objective of this study is to demonstrate the effectiveness and tolerability of the buprenorphine transdermal system (20 mg) in comparison to the buprenorphine transdermal system (5 mg) and oxycodone immediate release in subjects with moderate to severe osteoarthritis pain currently treated with oral opioids. The double-blind treatment intervention duration is 12 weeks during which time supplemental analgesic medication (acetaminophen, ibuprofen, immediate release oxycodone) will be provided to all subjects in addition to study drug.
Buprenorphine is a synthetic opioid analgesic with over twenty-five years of international clinical experience indicating it to be safe and effective in a variety of therapeutic situations for the relief of moderate to severe pain.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-specific exclusion/inclusion criteria may apply.
Buprenorphine transdermal patch 5 mcg/h applied for 7-day wear
Drug: Buprenorphine
Buprenorphine transdermal patch 20 mcg/h applied for 7-day wear
Drug: Buprenorphine
Oxycodone immediate-release 40 mg (two 5-mg capsules every 6 hours).
Drug: oxycodone immediate-release
Buprenorphine transdermal patch 5 mcg/h applied for 7-day wear
Also known as: Butrans™
Buprenorphine transdermal patch 20 mcg/h applied for 7-day wear
Also known as: Butrans™
Oxycodone immediate-release 40 mg (two 5-mg capsules every 6 hours).
"Average Pain Over the Last 24 Hours" Scores at Weeks 4, 8, and 12 of the Double-blind Phase.
The "average pain over the last 24 hours" score was collected using an 11-point numerical scale ranging from 0 to 10, where 0 = no pain and 10 = pain as bad as you can imagine. This variable was obtained at each clinic visit during the double-blind phase of the study (postrandomization weeks 1, 2, 4, 8, and 12).
Time frame: Weeks 4, 8, and 12 of the double-blind phase
The Mean Daily Number of Supplemental Analgesic Medication Tablets
The mean daily number of supplemental analgesic medication tablets included sponsor-supplied ibuprofen, acetaminophen, or OxyIR®.
Time frame: Double-blind phase (84 days)
The Physical Function Subscale of The Western Ontario and McMaster's Universities Osteoarthritis (WOMAC OA) Index at Weeks 4, 8, and 12 of the Double Blind Phase
The WOMAC (Version LK 3.1) measures symptoms and physical functioning of patients with OA of the hip and knee. It contains 24 items (5 pain, 2 stiffness, 17 physical function) and takes less than 5 minutes to complete. The WOMAC physical function subscale has 17 items coded as 0 to 4 (best to worst), which are summed, giving a range of 0 to 68 (best to worst).
Time frame: Weeks 4, 8 and 12 of the double-blind phase
The Sleep Disturbance Subscale in The Medical Outcomes (MOS)-Sleep Scale at Weeks 4, 8, and 12 of the Double-blind Phase
The MOS-Sleep Scale consists of 12 individual items: (4 sleep disturbance, 2 sleep adequacy, 1 quantity of optimal sleep, 3 somnolence, 1 snoring, and 1 shortness of breath) and takes 5 to 10 minutes to complete. Question 1 is scored on a scale of 1 to 5 and Questions 2 to 12 are scored on a scale of 1 to 6. The Sleep Disturbance Subscale score is derived from the scores to Questions 1, 3, 7 and 8, and ranges from 0 to 100, where higher scores indicate greater sleep disturbance.
Time frame: Weeks 4, 8, and 12 of the Double-blind Phase
Study Dates: 02-Apr-2004 (first subject first visit) to 18 Jul-2005 (last subject last visit); 15-Jun-2005 (first site notified of study termination). The study took place in 82 medical/research sites in the US; 59 sites randomized at least 1 subject.
| Milestone | Run-in Period | Double-blind BTDS 5 | Double-blind BTDS 20 | Double-blind Oxycodone Immediate-Release |
|---|---|---|---|---|
| Started | 652 | 0 | 0 | 0 |
| Completed | 418 | 0 | 0 | 0 |
| Not completed | 234 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 6 | 0 | 0 | 0 |
| Withdrew: Adverse event | 74 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 5 | 0 | 0 | 0 |
| Withdrew: Administrative | 42 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 102 | 0 | 0 | 0 |
| Withdrew: Did not qualify | 5 | 0 | 0 | 0 |
| Milestone | Run-in Period | Double-blind BTDS 5 | Double-blind BTDS 20 | Double-blind Oxycodone Immediate-Release |
|---|---|---|---|---|
| Started | 0 | 136 | 149 | 133 |
| Completed | 0 | 77 | 77 | 63 |
| Not completed | 0 | 59 | 72 | 70 |
| Withdrew: Withdrawal by subject | 0 | 6 | 8 | 7 |
| Withdrew: Adverse event | 0 | 10 | 19 | 18 |
| Withdrew: Lost to follow-up | 0 | 0 | 2 | 2 |
| Withdrew: Administrative | 0 | 26 | 37 | 33 |
| Withdrew: Lack of efficacy | 0 | 17 | 6 | 10 |
The "average pain over the last 24 hours" score was collected using an 11-point numerical scale ranging from 0 to 10, where 0 = no pain and 10 = pain as bad as you can imagine. This variable was obtained at each clinic visit during the double-blind phase of the study (postrandomization weeks 1, 2, 4, 8, and 12).
| Units on a scale | Double-blind BTDS 5 | Double-blind BTDS 20 | Double-blind Oxycodone Immediate-Release |
|---|---|---|---|
| Screening | 6.60 ± 0.116 | 6.58 ± 0.103 | 6.44 ± 0.117 |
| Prerandomization | 3.25 ± 0.114 | 3.02 ± 0.093 | 3.03 ± 0.099 |
| Week 4 | 4.21 ± 0.219 | 3.57 ± 0.195 | 3.45 ± 0.209 |
| Week 8 | 3.78 ± 0.239 | 3.37 ± 0.190 | 3.59 ± 0.217 |
| Week 12 | 3.67 ± 0.246 | 3.56 ± 0.230 | 3.37 ± 0.232 |
The mean daily number of supplemental analgesic medication tablets included sponsor-supplied ibuprofen, acetaminophen, or OxyIR®.
| Tablets | Double-blind BTDS 5 | Double-blind BTDS 20 | Double-blind Oxycodone Immediate-Release |
|---|---|---|---|
| Prerandomization | 2.0 ± 0.19 | 1.7 ± 0.13 | 1.6 ± 0.13 |
| Double-blind | 3.3 ± 0.26 | 2.3 ± 0.19 | 2.3 ± 0.22 |
The WOMAC (Version LK 3.1) measures symptoms and physical functioning of patients with OA of the hip and knee. It contains 24 items (5 pain, 2 stiffness, 17 physical function) and takes less than 5 minutes to complete. The WOMAC physical function subscale has 17 items coded as 0 to 4 (best to worst), which are summed, giving a range of 0 to 68 (best to worst).
| Units on a scale | Double-blind BTDS 5 | Double-blind BTDS 20 | Double-blind Oxycodone Immediate-Release |
|---|---|---|---|
| Screening | 36.88 ± 1.093 | 37.69 ± 0.930 | 36.81 ± 1.043 |
| Prerandomization | 25.96 ± 0.993 | 24.19 ± 0.947 | 24.42 ± 0.930 |
| Week 4 | 30.60 ± 1.187 | 28.34 ± 1.025 | 26.65 ± 1.253 |
| Week 8 | 28.70 ± 1.364 | 28.34 ± 1.199 | 26.59 ± 1.405 |
| Week 12 | 29.68 ± 1.500 | 29.35 ± 1.253 | 27.25 ± 1.651 |
The MOS-Sleep Scale consists of 12 individual items: (4 sleep disturbance, 2 sleep adequacy, 1 quantity of optimal sleep, 3 somnolence, 1 snoring, and 1 shortness of breath) and takes 5 to 10 minutes to complete. Question 1 is scored on a scale of 1 to 5 and Questions 2 to 12 are scored on a scale of 1 to 6. The Sleep Disturbance Subscale score is derived from the scores to Questions 1, 3, 7 and 8, and ranges from 0 to 100, where higher scores indicate greater sleep disturbance.
| Units on a scale | Double-blind BTDS 5 | Double-blind BTDS 20 | Double-blind Oxycodone Immediate-Release |
|---|---|---|---|
| Screening | 51.91 ± 2.139 | 55.28 ± 2.035 | 55.74 ± 2.197 |
| Prerandomization | 34.64 ± 1.950 | 28.65 ± 1.782 | 33.03 ± 1.926 |
| Week 4 | 39.23 ± 2.144 | 32.40 ± 1.941 | 35.72 ± 2.298 |
| Week 8 | 35.95 ± 2.791 | 31.71 ± 2.473 | 34.13 ± 2.746 |
| Week 12 | 39.13 ± 3.089 | 32.95 ± 2.819 | 36.32 ± 3.290 |
Collected over Adverse Events (AEs) occurring after the signing of informed consent up to study completion or discontinuation; during 7 days after last visit; serious AEs up to 30 days following the last study visit were followed until the event resolved.. Non-serious events are listed at a 4.50% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Double-blind BTDS 5 | — | 3/136 (2.2%) | 30/136 (22.1%) |
| Double-blind BTDS 20 | — | 7/149 (4.7%) | 70/149 (47%) |
| Double-blind Oxycodone Immediate-Release | — | 7/133 (5.3%) | 56/133 (42.1%) |
| Run-in, Open-label BTDS 10 and 20 | — | 8/652 (1.2%) | 187/652 (28.7%) |
| Event | Double-blind BTDS 5 | Double-blind BTDS 20 | Double-blind Oxycodone Immediate-Release | Run-in, Open-label BTDS 10 and 20 |
|---|---|---|---|---|
| Acute abdomenGastrointestinal disorders | 0/136 | 0/149 | 1/133 | 0/652 |
| Acute renal failureRenal and urinary disorders | 0/136 | 0/149 | 1/133 | 0/652 |
| Acute cholecystitisHepatobiliary disorders | 0/136 | 0/149 | 1/133 | 0/652 |
| DehydrationMetabolism and nutrition disorders | 0/136 | 0/149 | 1/133 | 0/652 |
| DiarrheaGastrointestinal disorders | 0/136 | 0/149 | 1/133 | 0/652 |
| FellGeneral disorders | 0/136 | 0/149 | 1/133 | 0/652 |
| Fractured left hipInjury, poisoning and procedural complications | 0/136 | 0/149 | 1/133 | 0/652 |
| GI bleedingGastrointestinal disorders | 0/136 | 0/149 | 1/133 | 0/652 |
| Recurrent L4-L5 disc herniationMusculoskeletal and connective tissue disorders | 0/136 | 0/149 | 1/133 | 0/652 |
| Recurrent L5-S1 disc herniation with impingement of the S1 nerve rootNervous system disorders | 0/136 | 0/149 | 1/133 | 0/652 |
| Event | Double-blind BTDS 5 | Double-blind BTDS 20 | Double-blind Oxycodone Immediate-Release | Run-in, Open-label BTDS 10 and 20 |
|---|---|---|---|---|
| Application site pruritusGeneral disorders | 13/136 | 22/149 | 12/133 | 47/652 |
| HeadacheNervous system disorders | 10/136 | 22/149 | 16/133 | 70/652 |
| NauseaGastrointestinal disorders | 4/136 | 16/149 | 17/133 | 94/652 |
| Application site erythemaGeneral disorders | 9/136 | 14/149 | 5/133 | 9/652 |
| SomnolenceNervous system disorders | 2/136 | 2/149 | 10/133 | 29/652 |
| ConstipationGastrointestinal disorders | 3/136 | 8/149 | 9/133 | 22/652 |
| DizzinessNervous system disorders | 4/136 | 10/149 | 7/133 | 43/652 |
| Application site rashGeneral disorders | 5/136 | 9/149 | 8/133 | 9/652 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 5/136 | 9/149 | 4/133 | 12/652 |
| Upper respiratory tract infection NOSInfections and infestations | 6/136 | 6/149 | 8/133 | 5/652 |
| Age Continuous(years) | Double-blind BTDS 5 | Double-blind BTDS 20 | Double-blind Oxycodone Immediate-Release | Total |
|---|---|---|---|---|
| Mean | 58.7 ± 10.71 | 57.9 ± 9.45 | 58.1 ± 10.36 | 58.3 ± 10.15 |
| Sex: Female, Male(Participants) | Double-blind BTDS 5 | Double-blind BTDS 20 | Double-blind Oxycodone Immediate-Release | Total |
|---|---|---|---|---|
| Female | 101 | 116 | 94 | 311 |
| Male | 35 | 33 | 39 | 107 |
The record gives a start of Apr 2004, a primary completion of Jul 2005 and a completion of Aug 2005. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2010, 5 years 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Sep 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Buprenorphine